Anika Therapeutics, Inc. (ANIK) Return on equity 2016–2025
Anika Therapeutics, Inc. (ANIK) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-7.6%FY2025 · since FY2016: 14.6% → -7.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.6% | +29.0 pp |
| FY2024 | -36.6% | +2.3 pp |
| FY2023 | -38.9% | -33.7 pp |
| FY2022 | -5.2% | -6.6 pp |
| FY2021 | 1.4% | +10.2 pp |
| FY2020 | -8.8% | -18.2 pp |
| FY2019 | 9.4% | +2.3 pp |
| FY2018 | 7.1% | -5.0 pp |
| FY2017 | 12.1% | -2.5 pp |
| FY2016 | 14.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIK financial trends
ANIK RevenueANIK Net incomeANIK Net marginANIK Gross profitANIK Gross marginANIK Operating incomeANIK Operating marginANIK Operating cash flowANIK Free cash flowANIK Capital expendituresANIK Stock buybacksANIK Dividends paidANIK Total assetsANIK Total liabilitiesANIK Shareholders’ equityANIK overview →